Carmichael Roberts is a General Partner at North Bridge Venture Partners where he finances and builds companies that make new products using chemistry, materials science and/or materials engineering. Prior to joining North Bridge, Carmichael co-founded several companies including Arsenal Medical, Surface Logix, Nano-Terra, and Ancora. He has served in an executive and/or active board capacity for each of his companies.
Before starting his career as an entrepreneur, Carmichael worked in business development at GelTex Pharmaceuticals (acquired by Genzyme). Prior to GelTex, Carmichael was responsible for new product and business development at Sentry Products, a life science venture wholly owned by Union Carbide Corporation (acquired by Dow Chemical).
Carmichael is also very dedicated to developing medical products for developing nations. Along with Harvard University, Carmichael co-founded Diagnostics For All, Inc., a non-profit organization that is developing a materials platform to make low cost diagnostics for poor and rural populations in developing nations. He currently serves as Chairman of this organization.
Carmichael serves on the advisory boards for MIT’s Deshpande Center for Innovation, Harvard’s Nanoscale Science and Engineering Center, and Duke’s School of Biomedical Engineering. In 1999, he was named by MIT’s Technology Review as one of the world’s top 100 young entrepreneurs.
Carmichael received his B.S. and Ph.D. in organic chemistry from Duke University and was a national Science Foundation Fellow at Harvard University’s Department of Chemistry and Chemical Biology. He also earned his M.B.A. from the MIT Sloan School of Management.